Azalea Therapeutics Overview
- Year Founded
-
2023
- Status
-
Private
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$65M
- Investors
-
5
Azalea Therapeutics General Information
Description
Operator of a biotechnology platform intended to enable precise genome editing inside the body for disease treatment. The company offers an Enveloped Delivery Vehicle technology that directs CRISPR-Cas9 cargo to specific cells, enabling patients with cancer, autoimmune, and genetic conditions to receive targeted and sustained therapies.
Contact Information
Website
azaleatx.comCorporate Office
- 2625 Durant Avenue
- Berkeley, CA 94720
- United States
Corporate Office
- 2625 Durant Avenue
- Berkeley, CA 94720
- United States
Azalea Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series A) | 30-Oct-2025 | $65M | Completed | Startup | ||
| 3. Grant | Completed | Startup | ||||
| 2. Seed Round | 01-Jan-2023 | $17M | $17M | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2023 | Completed | Startup |
Azalea Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Azalea Therapeutics Patents
Azalea Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236280-A1 | In the united states patent and trademark office | Pending | 05-May-2025 | ||
| WO-2026178423-A2 | T cell-targeted delivery vehicles | Pending | 20-Feb-2025 | ||
| WO-2026178423-A3 | T cell-targeted delivery vehicles | Pending | 20-Feb-2025 | ||
| AU-2022208037-A1 | Aav vectors targeting t-cells | Pending | 14-Jan-2021 | ||
| AU-2022208037-A9 | Aav vectors targeting t-cells | Pending | 14-Jan-2021 |
Azalea Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| RA Capital Management | Asset Manager | Minority | ||
| Sozo Ventures | Venture Capital | Minority | ||
| Third Rock Ventures | Venture Capital | Minority | ||
| Yosemite | Venture Capital | Minority | ||
| University of California, Berkeley | University |
Azalea Therapeutics FAQs
-
When was Azalea Therapeutics founded?
Azalea Therapeutics was founded in 2023.
-
Where is Azalea Therapeutics headquartered?
Azalea Therapeutics is headquartered in Berkeley, CA.
-
What industry is Azalea Therapeutics in?
Azalea Therapeutics’s primary industry is Biotechnology.
-
Is Azalea Therapeutics a private or public company?
Azalea Therapeutics is a Private company.
-
What is the current valuation of Azalea Therapeutics?
The current valuation of Azalea Therapeutics is .
-
What is Azalea Therapeutics’s current revenue?
The current revenue for Azalea Therapeutics is .
-
How much funding has Azalea Therapeutics raised over time?
Azalea Therapeutics has raised $82M.
-
Who are Azalea Therapeutics’s investors?
RA Capital Management, Sozo Ventures, Third Rock Ventures, Yosemite, and University of California, Berkeley have invested in Azalea Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process